What does this research mean for the field?

Selumetinib treatment does not impair pulmonary function in children and young adults with neurofibromatosis type 1, suggesting that routine serial spirometry is unnecessary for monitoring thoracic plexiform neurofibromas. Novelty: ClaimNovelty.CONTRADICTORY. Consensus alignment: ConsensusAlignment.CHALLENGES_CONSENSUS.

What question did this study set out to answer?

The study aims to assess pulmonary function trends and respiratory adverse events in pediatric patients with neurofibromatosis type 1 undergoing selumetinib treatment.

July 15, 2026The Italian Journal of Pediatrics/Italian journal of pediatricsOpen Access

Respiratory function in children and young adults affected by neurofibromatosis type 1 treated with selumetinib

View Full Paper

Ask AI

Bookmark

Authors

EZElettra ZulianiUniversity of Trieste FBFrancesco BaldoUniversity of Trieste SGSergio GhirardoUniversity of Trieste

Discussion

Member takes

Implication

Retrospective study investigates pulmonary function outcomes in pediatric neurofibromatosis patients treated with selumetinib, indicating no significant impairments.

Key Points

The study aims to assess pulmonary function trends and respiratory adverse events in pediatric patients with neurofibromatosis type 1 undergoing selumetinib treatment.
Retrospective study design conducted at a pediatric department in Italy.
Analysis included patients diagnosed with neurofibromatosis type 1 who received selumetinib and were able to perform spirometry.
Measured forced vital capacity (FVC) and forced expiratory volume (FEV1) over two years of follow-up.
21 pediatric patients treated with selumetinib showed no pulmonary symptoms during follow-up.
No significant spirometry value changes detected after treatment.
No correlation found between spirometry metrics and neurofibromas' volumetric changes observed via MRI.

Cite This Study

Zuliani et al. (2026) studied this question.

synapsesocial.com/papers/6a57245a88b21df875480b8b https://doi.org/10.1186/s13052-026-02297-4

View Full Paper

Ask AI

Bookmark

Implication

Retrospective study investigates pulmonary function outcomes in pediatric neurofibromatosis patients treated with selumetinib, indicating no significant impairments.

Respiratory function in children and young adults affected by neurofibromatosis type 1 treated with selumetinib

Discussion

Member takes

Implication

Key Points

Cite This Study

Respiratory function in children and young adults affected by neurofibromatosis type 1 treated with selumetinib

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider